|Table of Contents|

Decreased expression of protein tyrosine phosphatase receptor O correlates with epidermal growth factor receptor 2 in breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 05
Page:
721-723
Research Field:
Publishing date:

Info

Title:
Decreased expression of protein tyrosine phosphatase receptor O correlates with epidermal growth factor receptor 2 in breast cancer
Author(s):
Li Wenmei1; Liu Jiajia1; Zhang Yinpo2
1.Department of Pharmacy；2.Pathological Diagnosis and Research Center，Luohe Medical College，Henan Luohe 462000，China.
Keywords:
PTPRO; HER2; breast cancer; immunohistochemistry
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2017.05.013
Abstract:
Objective：To examine the expression status of protein tyrosine phosphatase receptor O (PTPRO)，human epidermal growth factor receptor 2 (HER2) and their potential clinical significance human breast cancer.Methods： Immuno-expression of PTPRO and HER2 were detected by immunohistochemistry (IHC) analysis in 50 primary breast cancer tissues.The relationship of the expression between PTPRO and HER2 with clinical pathological parameters were analyzed.Results： PTPRO and HER2 expression were observed in 40.0%（20/50）and 68%（34/50）of the primary breast cancer tissues，respectively.Loss of PTPRO expression was correlated with lymph node metastasis and progesterone receptor (PR) expression.HER2 expression was correlated with tumor size，lymph node metastasis and PR expression.Additionally，a negative correlation was found between PTPRO and HER2 expression.Conclusion： PTPRO and HER2 expression were signicantly associated with the clinicopathologic features in breast cancer.

References:

［1］Gupta GP，Massagué J.Cancer metastasis：building a framework［J］.Cell，2006，127：679-695.
［2］Bargmann CI，Hung MC，Weinberg RA.The neu oncogene encodes an epidermal growth factor receptor-related protein［J］.Nature，1986，319：226-230.
［3］Press MF，Slamon DJ，Flom KJ，et al.Evaluation of HER-2/neu gene amplification and overexpression：comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens［J］.J Clin Oncol，2002，20：3095-3105.
［4］Yu M，Lin G，Arshadi N，et al.Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation［J］.Mol Cell Biol，2012，32(19)：3913-3924.
［5］You Y，Chen Y，Zheng X，et al.Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients［J］.Cancer Lett，2012，315(2)：138-144.
［6］Huang YT，Li FF，Ke C，et al.PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer：indication for personalized therapy［J］.J Transl Med，2013，11：245.
［7］Yu M，Lin G，Arshadi N，et al.Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation［J］.Mol Cell Biol，2012，32(19)：3913-3924.
［8］Hou J，Xu J，Jiang R，et al.Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3［J］.Hepatology，2013，57：678-688.
［9］Li Z，Zou X，Xie L，et al.Prognostic importance and therapeutic implications of PAK1，a drugable protein kinase，in gastroesophageal junction adenocarcinoma［J］.PLoS One，2013，8：e80665.
［10］Horii R，Akiyama F，Ito Y，et al.Assessment of hormone receptor status in breast cancer［J］.Pathol Int，2007，57(12)：784-790.
［11］Hou J，Deng L，Zhuo H，et al.PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma［J］.J Mol Cell Biol，2015，7(4)：338-350.
［12］Zhang W，Hou J，Wang X，et al.PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis［J］.Oncotarget，2015，6(11)：9420-9433.
［13］Jiang R，Chen D，Hou J，et al.Survival and inflammation promotion effect of PTPRO in fulminant hepatitis is associated with NF-κB activation［J］.J Immunol，2014，193(10)：5161-5170.

Memo

Memo:
河南省高等学校重点科研项目（编号：15B320003）
Last Update: 2017-01-26